Zura Bio Limited (NASDAQ:ZURA) Stock Has Average Target Price of $17.00

Key Points

• Zura Bio has a “Moderate Buy” consensus rating from seven analysts, with five buys, one strong buy and one sell; the average 12-month price target is $17.00.
• Institutional investors own 61.14% of the company, with several funds increasing their positions, including Bank of America, Dimensional Fund Advisors and ADAR1 Capital Management.
• Zura Bio shares opened at $3.93, down 4.4%, compared with a 52-week range of $3.15 to $7.44. The clinical-stage biotechnology company reported a quarterly loss of $0.21 per share and is expected to post a full-year loss of $0.81 per share.

Zura Bio Limited (NASDAQ:ZURA - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven ratings firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $17.00.

Several equities analysts recently issued reports on ZURA shares. Weiss Ratings restated a "sell (d-)" rating on shares of Zura Bio in a research note on Friday. Wedbush boosted their target price on shares of Zura Bio from $15.00 to $22.00 and gave the company an "outperform" rating in a research note on Wednesday, August 12th. William Blair initiated coverage on shares of Zura Bio in a report on Wednesday, July 8th. They issued an "outperform" rating for the company. Wall Street Zen raised shares of Zura Bio from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 1st. Finally, Guggenheim raised their target price on shares of Zura Bio from $15.00 to $20.00 and gave the stock a "buy" rating in a report on Wednesday, August 12th.

Institutional Trading of Zura Bio

Hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC grew its position in Zura Bio by 3.4% in the 1st quarter. Renaissance Technologies LLC now owns 313,300 shares of the company's stock worth $1,864,000 after purchasing an additional 10,200 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Zura Bio by 83.3% during the first quarter. Dimensional Fund Advisors LP now owns 43,135 shares of the company's stock valued at $257,000 after buying an additional 19,603 shares during the last quarter. ADAR1 Capital Management LLC boosted its position in shares of Zura Bio by 12.2% during the first quarter. ADAR1 Capital Management LLC now owns 630,403 shares of the company's stock worth $3,751,000 after buying an additional 68,338 shares during the period. Bank of America Corp DE boosted its position in shares of Zura Bio by 3,007.7% during the first quarter. Bank of America Corp DE now owns 136,523 shares of the company's stock worth $812,000 after buying an additional 132,130 shares during the period. Finally, Seven Fleet Capital Management LP bought a new position in Zura Bio in the 4th quarter worth approximately $872,000. Institutional investors own 61.14% of the company's stock.

Zura Bio Stock Down 4.4%

Shares of Zura Bio stock opened at $3.93 on Tuesday. The firm has a market cap of $376.61 million, a P/E ratio of -3.48 and a beta of 0.01. Zura Bio has a fifty-two week low of $3.15 and a fifty-two week high of $7.44. The business has a 50-day moving average price of $5.30 and a 200 day moving average price of $5.09.

Zura Bio (NASDAQ:ZURA - Get Free Report) last announced its quarterly earnings data on Tuesday, June 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. As a group, equities research analysts anticipate that Zura Bio will post -0.81 earnings per share for the current year.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on developing medicines for chronic immune-mediated diseases. The company's research programs are designed to address conditions in which abnormal immune responses contribute to inflammation and tissue damage.

Zura Bio is advancing a pipeline of investigational antibody-based therapies for diseases including hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis and systemic sclerosis. Its programs target biological pathways involved in inflammation, with the goal of developing treatments for patients who may not respond adequately to existing therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.